Biocartis

Biocartis company information, Employees & Contact Information

Explore related pages

Related company profiles:

Biocartis is an innovative molecular diagnostics company committed to revolutionizing molecular testing with its unique proprietary IdyllaTM Platform. We provide next generation diagnostic solutions, aimed at improving clinical practice for the benefit of patients, clinicians, payers and the healthcare industry, with a focus in oncology. Today, Biocartis offers tests supporting melanoma, colorectal, lung, breast, thyroid, brain and blood cancer. Biocartis is headquartered in Mechelen, Belgium.

Company Details

Employees
310
Founded
-
Address
Generaal De Wittelaan,
Phone
41 21 694 04 30
Email
in****@****tis.com
Industry
Medical Equipment Manufacturing
NAICS
Medical Equipment and Supplies Manufacturing
Surgical and Medical Instrument Manufacturing
Surgical Appliance and Supplies Manufacturing
Dental Equipment and Supplies Manufacturing
Ophthalmic Goods Manufacturing
Dental Laboratories
HQ
Mechelen
Looking for a particular Biocartis employee's phone or email?

Biocartis Questions

News

Press Release Biocartis NV: Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test - Yahoo Finance

Press Release Biocartis NV: Biocartis Receives FDA Approval for the Idylla™ CDx MSI Test Yahoo Finance

Press Release Biocartis NV: Biocartis Welcomes Mike - GlobeNewswire

Press Release Biocartis NV: Biocartis Welcomes Mike GlobeNewswire

FDA Grants Premarket Approval to Idylla CDx MSI Test for MSI-H CRC - OncLive

FDA Grants Premarket Approval to Idylla CDx MSI Test for MSI-H CRC OncLive

W. Michael Korn: Biocartis Received FDA Approval for the Idylla CDx MSI Test - Oncodaily

W. Michael Korn: Biocartis Received FDA Approval for the Idylla CDx MSI Test Oncodaily

FDA greenlights diagnostic from Biocartis, BMS to find immunotherapy eligible patients - FirstWord Pharma

FDA greenlights diagnostic from Biocartis, BMS to find immunotherapy eligible patients FirstWord Pharma

Press Release Biocartis NV: Biocartis Welcomes Ben Svarczkopf as Senior Vice President of Global Marketing - GlobeNewswire

Press Release Biocartis NV: Biocartis Welcomes Ben Svarczkopf as Senior Vice President of Global Marketing GlobeNewswire

Biocartis receives FDA approval for Idylla CDx MSI test - Indian Pharma Post

Biocartis receives FDA approval for Idylla CDx MSI test Indian Pharma Post

Press Release Biocartis NV: Biocartis Announces IVDR Class C CDx Certification of the Idylla™ EGFR Mutation Test - GlobeNewswire

Press Release Biocartis NV: Biocartis Announces IVDR Class C CDx Certification of the Idylla™ EGFR Mutation Test GlobeNewswire

Biocartis Introduces Influenza-Respiratory Virus Panel on Idylla Platform - respiratory-therapy.com

Biocartis Introduces Influenza-Respiratory Virus Panel on Idylla Platform respiratory-therapy.com

Biocartis’ EGFR Mutation Test gains IVDR Class C CDx certification - Medical Device Network

Biocartis’ EGFR Mutation Test gains IVDR Class C CDx certification Medical Device Network

Genomic Health and Biocartis Announce Agreement to Develop an Idylla™ IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access - PR Newswire

Genomic Health and Biocartis Announce Agreement to Develop an Idylla™ IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access PR Newswire

Biocartis starts European commercialization of liver cancer test - Labiotech.eu

Biocartis starts European commercialization of liver cancer test Labiotech.eu

Press Release Biocartis NV: Biocartis appoints Randy Polonsky as Chief Financial Officer - Yahoo Finance

Press Release Biocartis NV: Biocartis appoints Randy Polonsky as Chief Financial Officer Yahoo Finance

Press Release Biocartis NV: Biocartis Announces Multiple Abstracts Demonstrating the Impact of Idylla™ in Oncology Diagnostics to be Presented at USCAP 2025 Annual Meeting - GlobeNewswire

Press Release Biocartis NV: Biocartis Announces Multiple Abstracts Demonstrating the Impact of Idylla™ in Oncology Diagnostics to be Presented at USCAP 2025 Annual Meeting GlobeNewswire

Michael Korn has joined Biocartis NV as its Chief Medical and Scientific Officer - Oncodaily

Michael Korn has joined Biocartis NV as its Chief Medical and Scientific Officer Oncodaily

Press Release Biocartis NV: Biocartis Announces Launch of the Brand-New Idylla™ POLE-POLD1 Mutation Assay - GlobeNewswire

Press Release Biocartis NV: Biocartis Announces Launch of the Brand-New Idylla™ POLE-POLD1 Mutation Assay GlobeNewswire

Press release Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion - Yahoo Finance

Press release Biocartis Holdings Inc.: Recapitalization completed and product portfolio expansion Yahoo Finance

Press Release Biocartis NV: Biocartis announces new data on early CAR-T vector load assessment with Idylla™ presented at ASTCT: A Potential Breakthrough in LBCL Treatment Monitoring - GlobeNewswire

Press Release Biocartis NV: Biocartis announces new data on early CAR-T vector load assessment with Idylla™ presented at ASTCT: A Potential Breakthrough in LBCL Treatment Monitoring GlobeNewswire

DC Advisory advises Biocartis on enforcement by secured creditors and recapitalization of its main operating subsidiaries - DC Advisory

DC Advisory advises Biocartis on enforcement by secured creditors and recapitalization of its main operating subsidiaries DC Advisory

DC Advisory advised creditors on the EUR 200M+ comprehensive recapitalization of Biocartis Group NV - DC Advisory

DC Advisory advised creditors on the EUR 200M+ comprehensive recapitalization of Biocartis Group NV DC Advisory

Ben Svarczkopf - PharmaTimes

Ben Svarczkopf PharmaTimes

Biocartis to Slash 25% of Workforce - Medical Device and Diagnostic industry

Biocartis to Slash 25% of Workforce Medical Device and Diagnostic industry

FDA Clears SeptiCyte® RAPID - The First One-Hour, Direct-from-Blood Sepsis Test - PR Newswire

FDA Clears SeptiCyte® RAPID - The First One-Hour, Direct-from-Blood Sepsis Test PR Newswire

FDA Approves Biocartis’ Idylla CDx MSI Test - Medical Product Outsourcing

FDA Approves Biocartis’ Idylla CDx MSI Test Medical Product Outsourcing

Why Biocartis Group NV (8XB) stock stays on buy lists - July 2025 Sentiment & Safe Entry Trade Signal Reports - Trung tâm Dự báo KTTV quốc gia

Why Biocartis Group NV (8XB) stock stays on buy lists - July 2025 Sentiment & Safe Entry Trade Signal Reports Trung tâm Dự báo KTTV quốc gia

Why Biocartis Group NV (8XB) stock stays on buy lists - Weekly Trade Report & Safe Entry Zone Identification - Trung tâm Dự báo KTTV quốc gia

Why Biocartis Group NV (8XB) stock stays on buy lists - Weekly Trade Report & Safe Entry Zone Identification Trung tâm Dự báo KTTV quốc gia

Why Biocartis Group NV (8XB) stock stays on buy lists - Quarterly Trade Review & Consistent Return Investment Signals - Trung tâm Dự báo KTTV quốc gia

Why Biocartis Group NV (8XB) stock stays on buy lists - Quarterly Trade Review & Consistent Return Investment Signals Trung tâm Dự báo KTTV quốc gia

Belgian and US Biotechs Team up to Reduce CAR T Side Effects - Labiotech.eu

Belgian and US Biotechs Team up to Reduce CAR T Side Effects Labiotech.eu

Biocartis raises €80M to help drive liquid biopsy push - Fierce Biotech

Biocartis raises €80M to help drive liquid biopsy push Fierce Biotech

Loss Report: Is Biocartis Group NV (8XB) stock a contrarian opportunity - 2025 Price Targets & Fast Entry Momentum Trade Alerts - Trung tâm Dự báo KTTV quốc gia

Loss Report: Is Biocartis Group NV (8XB) stock a contrarian opportunity - 2025 Price Targets & Fast Entry Momentum Trade Alerts Trung tâm Dự báo KTTV quốc gia

Biocartis’ Idylla test offers viable option for lung cancer diagnosis - Medical Device Network

Biocartis’ Idylla test offers viable option for lung cancer diagnosis Medical Device Network

Biocartis shareholders see their investment go up in smoke with planned stock market exit - MarketScreener

Biocartis shareholders see their investment go up in smoke with planned stock market exit MarketScreener

Horizon Discovery collaborates with Biocartis to offer reference standards for new Idylla MSI assay - News-Medical

Horizon Discovery collaborates with Biocartis to offer reference standards for new Idylla MSI assay News-Medical

Biocartis grabs lab space, staff from Johnson & Johnson to fuel U.S. expansion - Fierce Biotech

Biocartis grabs lab space, staff from Johnson & Johnson to fuel U.S. expansion Fierce Biotech

Biocartis, MRC Technology to Develop Liquid Biopsy Test for Breast Cancer - Inside Precision Medicine

Biocartis, MRC Technology to Develop Liquid Biopsy Test for Breast Cancer Inside Precision Medicine

Biocartis launches partnership in liquid biopsy - European Biotechnology Magazine

Biocartis launches partnership in liquid biopsy European Biotechnology Magazine

Biocartis attracts investors for $100m round - - Global Corporate Venturing

Biocartis attracts investors for $100m round - Global Corporate Venturing

Top Biocartis Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant